Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a current pandemic of unprecedented scale. Although diagnostic tests are fundamental to the ability to detect and respond, overwhelmed healthcare systems are already experiencing shortages of reagents associated with this test, calling for a lean immediately applicable protocol.
METHODS: RNA extracts of positive samples were tested for the presence of SARS-CoV-2 using reverse transcription quantitative polymerase chain reaction, alone or in pools of different sizes (2-, 4-, 8-, 16-, 32-, and 64-sample pools) with negative samples. Transport media of additional 3 positive samples were also tested when mixed with transport media of negative samples in pools of 8.
RESULTS: A single positive sample can be detected in pools of up to 32 samples, using the standard kits and protocols, with an estimated false negative rate of 10%. Detection of positive samples diluted in even up to 64 samples may also be attainable, although this may require additional amplification cycles. Single positive samples can be detected when pooling either after or prior to RNA extraction.
CONCLUSIONS: As it uses the standard protocols, reagents, and equipment, this pooling method can be applied immediately in current clinical testing laboratories. We hope that such implementation of a pool test for coronavirus disease 2019 would allow expanding current screening capacities, thereby enabling the expansion of detection in the community, as well as in close organic groups, such as hospital departments, army units, or factory shifts.
| Errataetall: |
CommentIn: Clin Infect Dis. 2021 May 4;72(9):e434. - PMID 32756932 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 16 vom: 19. Nov., Seite 2073-2078 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yelin, Idan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 14.12.2020 Date Revised 06.05.2021 published: Print CommentIn: Clin Infect Dis. 2021 May 4;72(9):e434. - PMID 32756932 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa531 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309425727 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309425727 | ||
| 003 | DE-627 | ||
| 005 | 20231225133901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa531 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309425727 | ||
| 035 | |a (NLM)32358960 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yelin, Idan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2020 | ||
| 500 | |a Date Revised 06.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2021 May 4;72(9):e434. - PMID 32756932 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a current pandemic of unprecedented scale. Although diagnostic tests are fundamental to the ability to detect and respond, overwhelmed healthcare systems are already experiencing shortages of reagents associated with this test, calling for a lean immediately applicable protocol | ||
| 520 | |a METHODS: RNA extracts of positive samples were tested for the presence of SARS-CoV-2 using reverse transcription quantitative polymerase chain reaction, alone or in pools of different sizes (2-, 4-, 8-, 16-, 32-, and 64-sample pools) with negative samples. Transport media of additional 3 positive samples were also tested when mixed with transport media of negative samples in pools of 8 | ||
| 520 | |a RESULTS: A single positive sample can be detected in pools of up to 32 samples, using the standard kits and protocols, with an estimated false negative rate of 10%. Detection of positive samples diluted in even up to 64 samples may also be attainable, although this may require additional amplification cycles. Single positive samples can be detected when pooling either after or prior to RNA extraction | ||
| 520 | |a CONCLUSIONS: As it uses the standard protocols, reagents, and equipment, this pooling method can be applied immediately in current clinical testing laboratories. We hope that such implementation of a pool test for coronavirus disease 2019 would allow expanding current screening capacities, thereby enabling the expansion of detection in the community, as well as in close organic groups, such as hospital departments, army units, or factory shifts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a disease surveillance | |
| 700 | 1 | |a Aharony, Noga |e verfasserin |4 aut | |
| 700 | 1 | |a Tamar, Einat Shaer |e verfasserin |4 aut | |
| 700 | 1 | |a Argoetti, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Messer, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Berenbaum, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Shafran, Einat |e verfasserin |4 aut | |
| 700 | 1 | |a Kuzli, Areen |e verfasserin |4 aut | |
| 700 | 1 | |a Gandali, Nagham |e verfasserin |4 aut | |
| 700 | 1 | |a Shkedi, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimshony, Tamar |e verfasserin |4 aut | |
| 700 | 1 | |a Mandel-Gutfreund, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Halberthal, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Geffen, Yuval |e verfasserin |4 aut | |
| 700 | 1 | |a Szwarcwort-Cohen, Moran |e verfasserin |4 aut | |
| 700 | 1 | |a Kishony, Roy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 16 vom: 19. Nov., Seite 2073-2078 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:16 |g day:19 |g month:11 |g pages:2073-2078 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa531 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 16 |b 19 |c 11 |h 2073-2078 | ||